

# **Project AI**

## **Introductory Overview**

---

October 2024

# Project AI | Company & Transaction Overview

- › Northland has been retained by experienced entrepreneurs building an AI-driven clinical assistant platform in the oncology space (“Project AI”, the “Company” or “Management”), whose goal is to raise capital to further fund their venture and / or seek a strategic investment.
- › The Company has developed a comprehensive ecosystem that integrates state-of-the-art NSG technologies with advanced AI algorithms to streamline the analysis of complex tumor gene expression data. Their platform generates personalized, ranked treatment options, empowering clinicians to make patient-specific treatment decisions in less time and with a higher degree of efficacy.
  - › The automation of gene expression data analysis reduces the time and resources required to make treatment decisions, generating cost savings for healthcare providers while simultaneously improving patient outcomes.
  - › The Company has filed provisional IP, launched the first iteration of their product, and formed key partnerships with top tier cancer research institutions, including the US National Cancer Institute. Clinical trials, oncologist feedback collection, and further product development are underway.
- › The Company is initially focused on addressing two prominent and hard-to-treat cancers, those being:
  - I. Pancreatic Cancer – One of the most aggressive cancers, with high mortality rates and no effective treatments.
  - II. Prostate Cancer – The 2<sup>nd</sup> leading cause of cancer death in American men, with limited treatment options.
- › The Company is seeking \$50.0MM in Seed / Series A funding to initiate captive NGS lab operations, support a full product launch, execute a broader marketing strategy, and scale operations. The Company is also receptive to promising M&A opportunities with complementary potential partners.

## Management Experience



# Project AI | Market & Strategy Overview


## Highlights

- > The precision oncology industry develops personalized cancer treatment approaches that leverage genetic insights and advanced technologies like AI and NSG to tailor treatments to patients.
- > This rapidly evolving field is transforming the way cancer is diagnosed and treated by improving accuracy, treatment efficacy, and overall patient outcomes.
- > The Company aims to capitalize upon this opportunity via a three phase development strategy:
  - I. Partner with oncologists and hospitals on a limited trial basis, and with research organizations for better precision in clinical trials and cancer research.
  - II. Partner with biotechs and pharmaceuticals for accelerated drug R&D.
  - III. Partner with Next Generation Sequencing (“NGS”) labs to provide value added reporting

## Key Metrics


### United States Precision Oncology TAM <sup>(1)</sup>

\$ USD in Billions




### Precision Medicine Share by Region <sup>(2)</sup>

FYE 2023



### Precision Medicine Share by Application <sup>(3)</sup>

FYE 2023



1) Grand View Research  
2) Precedence Research  
3) Expert Market Research

# Project AI | Key Investment Highlights

## Project AI

I

The Company represents a unique investment opportunity in the rapidly evolving field of oncology precision medicine.

II

Management has developed an innovative, AI-driven platform that has the potential to transform cancer treatment, improve patient outcomes, and drive efficiency and cost-effectiveness in healthcare.

III

The Company's platform addresses severe unmet patient demand in a rapidly growing market that offers dramatically increased treatment options.

IV

The Company's proprietary platform has first-mover advantage to deliver more efficient bioinformatics.

V

Project AI represents a breakthrough precision medicine platform that has the potential to drive significant value for the entire healthcare industry, including investors, companies, and patients.

VI

The Company's leadership comes from management, partnerships, biotech R&D, and software expertise, complemented by in-depth insights from advisors in the oncology field.

VII

The Company and their solutions target a markedly large TAM that is experiencing significant growth and is expected to continue growing well into the foreseeable future.

# Project AI | Disclosures & Contact Information

Northland Capital Markets is a division of Northland Securities, Inc., Member FINRA/SIPC, Registered with SEC and MSRB, and is a full-service capital markets group focused on growth companies and their institutional and accredited investors. Its investment banking services include public offerings of equity and convertible securities, PIPEs, CMPOs and registered direct offerings, private placements of equity and debt securities, and M&A advisory services. The research group provides in-depth research for leading small and mid-cap companies in growth sectors of the economy, with sector expertise in Business Services, Consumer, Energy, Healthcare, Industrial Growth, and Technology. Northland's institutional sales and trading group provides active market making and trading support in its targeted sectors and coverage companies.

## **CORPORATE OFFICE**

150 SOUTH FIFTH STREET, SUITE 3300

MINNEAPOLIS, MN 55402

PHONE NUMBER: 1.800.851.2920

All inquiries and requests for additional information regarding Project AI may be directed to the following Northland Capital Markets representatives:

**Pat Clemens**

Managing Director

(612) 460-4867

[pclemens@northlandcapitalmarkets.com](mailto:pclemens@northlandcapitalmarkets.com)

**Gavin Murphy**

Analyst

(612) 851-5954

[gmurphy@northlandcapitalmarkets.com](mailto:gmurphy@northlandcapitalmarkets.com)

**Harrison Wold**

Analyst

(612) 460-4857

[hwold@northlandcapitalmarkets.com](mailto:hwold@northlandcapitalmarkets.com)

**Grant Walnofer**

Analyst

(612) 851-4920

[gwalnofer@northlandcapitalmarkets.com](mailto:gwalnofer@northlandcapitalmarkets.com)

*In accordance with FINRA Rule 2241, Northland Capital Markets will never, directly or indirectly, offer favorable research, a specific rating or a specific price target, or threaten to change research, a rating or a price target, to a Company as consideration or inducement for the receipt of business or compensation*